Tags

Type your tag names separated by a space and hit enter

Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.
Neurology 2012; 78(17):1337-45Neur

Abstract

OBJECTIVE

To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: What pharmacologic therapies are proven effective for migraine prevention?

METHODS

The authors analyzed published studies from June 1999 to May 2009 using a structured review process to classify the evidence relative to the efficacy of various medications available in the United States for migraine prevention.

RESULTS AND RECOMMENDATIONS

The author panel reviewed 284 abstracts, which ultimately yielded 29 Class I or Class II articles that are reviewed herein. Divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol, and timolol are effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity (Level A). Frovatriptan is effective for prevention of menstrual migraine (Level A). Lamotrigine is ineffective for migraine prevention (Level A).

Authors+Show Affiliations

Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Practice Guideline
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

22529202

Citation

Silberstein, S D., et al. "Evidence-based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society." Neurology, vol. 78, no. 17, 2012, pp. 1337-45.
Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337-45.
Silberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E. (2012). Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology, 78(17), pp. 1337-45. doi:10.1212/WNL.0b013e3182535d20.
Silberstein SD, et al. Evidence-based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24;78(17):1337-45. PubMed PMID: 22529202.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. AU - Silberstein,S D, AU - Holland,S, AU - Freitag,F, AU - Dodick,D W, AU - Argoff,C, AU - Ashman,E, AU - ,, PY - 2012/4/25/entrez PY - 2012/4/25/pubmed PY - 2012/7/21/medline SP - 1337 EP - 45 JF - Neurology JO - Neurology VL - 78 IS - 17 N2 - OBJECTIVE: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: What pharmacologic therapies are proven effective for migraine prevention? METHODS: The authors analyzed published studies from June 1999 to May 2009 using a structured review process to classify the evidence relative to the efficacy of various medications available in the United States for migraine prevention. RESULTS AND RECOMMENDATIONS: The author panel reviewed 284 abstracts, which ultimately yielded 29 Class I or Class II articles that are reviewed herein. Divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol, and timolol are effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity (Level A). Frovatriptan is effective for prevention of menstrual migraine (Level A). Lamotrigine is ineffective for migraine prevention (Level A). SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/22529202/Evidence_based_guideline_update:_pharmacologic_treatment_for_episodic_migraine_prevention_in_adults:_report_of_the_Quality_Standards_Subcommittee_of_the_American_Academy_of_Neurology_and_the_American_Headache_Society_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&pmid=22529202 DB - PRIME DP - Unbound Medicine ER -